Journal
EXPERT REVIEW OF HEMATOLOGY
Volume 8, Issue 6, Pages 733-742Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2015.1087844
Keywords
anti-CD20 monoclonal antibody; biologics; biosimilars; CD20 antigen; chronic lymphocytic leukemia; immunomodulatory agents; indolent non-Hodgkin's lymphoma; small molecule kinase inhibitors
Categories
Funding
- Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital
- Roche-Genentech
Ask authors/readers for more resources
Chronic lymphocytic leukemia/small lymphocytic lymphoma is the most prevalent form of adult leukemia in western countries. Chemotherapy has been the mainstay of treatment for the last several decades. The introduction of biological, targeted agents (e.g., monoclonal antibodies) has dramatically improved treatment options. The addition of rituximab to fludarabine and cyclophosphamide has improved patient outcomes, as compared to fludarabine and cyclophosphamide. Nevertheless, chronic lymphocytic leukemia remains incurable, leaving considerable room for improvement. One approach would be to enhance the activity of the CD20 antibody. The next-generation monoclonal antibody ofatumumab has not demonstrated superiority over rituximab, whereas obinutuzumab-chlorambucil is superior to rituximab-chlorambucil. Recent efforts to combine anti-CD20 antibodies with new targeted therapies offer the potential to move toward alternative non-chemotherapy-based treatment approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available